NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Century Therapeutics, Inc. IPSC
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$109.2M
▲ 1556.8% vs FY2024
EPS · FY25
$-0.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-6.0%
Net margin · FY25
-8.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 109.2M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 9 cents on every revenue dollar this year.
Per share
USD -0.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-6.0%
Return on equity, FY2025
ROE
Operating margin-15.8%
Net margin-8.8%
Return on assets-3.3%
Each USD of equity lost 6 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+175.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 223.7M
total assets, end of FY2025
Total assetsUSD 223.7M
EquityUSD 158.9M
CashUSD 61.9M
Current ratio5.97×
Equity funds 71% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
−0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−0.14
−1.61
−2.30
−2.96
−2.96
−7.16
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−6.0
−73.1
−56.1
−37.5
−66.1
·
Shares out B
0.09
0.09
0.06
0.06
0.06
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
17 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed